Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | BAD | Q92934 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907036 | 0.83 | LMNA (0.35) | — | |
| SCHEMBL2750709 | 0.81 | NOTUM (0.38) | MAP4K4 | |
| SCHEMBL16033234 | 0.79 | MAPT (0.55) | RAB9ANPC1KDM4EARMAP4K4 | |
| SCHEMBL5541598 | 0.78 | CYP1A2 (0.41) | MAPK14GCGRRAB9ANPC1ALOX5 | |
| SCHEMBL6860806 | 0.78 | NISCH (0.39) | MAPK14GCGRRAB9ANPC1ALDH1A1 | |
| SCHEMBL16538551 | 0.78 | KIF11 (0.61) | — | |
| SCHEMBL2751878 | 0.78 | CYP11B2 (0.43) | MAPK14RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL121708 | 0.77 | NOTUM (0.50) | RAB9ANPC1BCL2L1ALDH1A1KDM4E | |
| SCHEMBL5542344 | 0.76 | TAAR1 (0.44) | MAPK14ALDH1A1KDM4EMAPK13MAPK12 | |
| SCHEMBL2750686 | 0.75 | TTR (0.37) | MAPK14RAB9ANPC1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351568-B2 | Compositions and methods for enhancing proteasome activity | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-07-16 | — | — | US | disclosed |
| US-10150742-B2 | Substituted heterocyclic compounds for treating or preventing viral infections | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180265519-A1 | TRICYCLIC PROTEASOME ACTIVITY ENHANCING COMPOUNDS | THE ASSAY DEPOT, INC. | 2018-09-20 | — | — | US | disclosed |
| US-9981981-B2 | Tricyclic proteasome activity enhancing compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-05-29 | — | — | US | disclosed |
| EP-2595993-B1 | TRICYCLIC PROTEASOME ACTIVITY ENHANCING COMPOUNDS | HARVARD COLLEGE (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9849135-B2 | USP14 inhibitors for treating or preventing viral infections | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2528911-B1 | COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY | HARVARD COLLEGE (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9643977-B2 | Necroptosis inhibitors and methods of use therefor | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160214989-A1 | Compositions and Methods for Enhancing Proteasome Activity | THE ASSAY DEPOT, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160039839-A1 | Tricyclic Proteasome Activity Enhancing Compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-02-11 | — | — | US | disclosed |
| US-20140066466-A1 | Necroptosis Inhibitors and Methods of Use Therefor | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130210845-A1 | Tricyclic Proteasome Activity Enhancing Compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2595993-A2 | TRICYCLIC PROTEASOME ACTIVITY ENHANCING COMPOUNDS | President and Fellows of Harvard College (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20130045992-A1 | Compositions and Methods for Enhancing Proteasome Activity | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-21 | — | — | US | disclosed |
| EP-2528911-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY | President and Fellows of Harvard College (US) | 2012-12-05 | — | — | EP | disclosed |
| WO-2012125544-A2 | NECROPTOSIS INHIBITORS AND METHODS OF USE THEREFOR | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012012712-A2 | TRICYCLIC PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2011094545-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-08-04 | — | — | WO | disclosed |
| CN-100475792-C | Novel gamma-secretase inhibitors | MERCK SHARP & DOHME (GB) | 2009-04-08 | — | — | CN | disclosed |
| CN-1832927-A | Novel gamma-secretase inhibitors | MERCK SHARP & DOHME (GB) | 2006-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066466-A1 | Necroptosis Inhibitors and Methods of Use Therefor | CD40, CD40LG, TNF | MAPK14 371/4885MAPK10 391/4885GCGR 1375/4885 |
| US-10351568-B2 | Compositions and methods for enhancing proteasome activity | PSMG3, PSME3, PSMB11 | MAPK14 1780/4885MAPK10 2679/4885GCGR 4577/4885 |
| US-20130045992-A1 | Compositions and Methods for Enhancing Proteasome Activity | PSMG3, PSMB11, PSME3 | MAPK14 1520/4885MAPK10 2667/4885GCGR 4576/4885 |
| US-20130210845-A1 | Tricyclic Proteasome Activity Enhancing Compounds | PSME3, PSME1, PSMG3 | MAPK14 1447/4885MAPK10 2415/4885GCGR 4701/4885 |
| US-10150742-B2 | Substituted heterocyclic compounds for treating or preventing viral infections | HAVCR2, DDX5, DPYD | MAPK14 2824/4885MAPK10 3366/4885GCGR 3633/4885 |
| US-20180265519-A1 | TRICYCLIC PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSME3, PSME1, PSMG3 | MAPK14 1447/4885MAPK10 2415/4885GCGR 4701/4885 |
| US-20160214989-A1 | Compositions and Methods for Enhancing Proteasome Activity | PSMG3, PSME3, PSMB11 | MAPK14 1780/4885MAPK10 2679/4885GCGR 4577/4885 |
| US-20160039839-A1 | Tricyclic Proteasome Activity Enhancing Compounds | PSME3, PSME1, PSMG3 | MAPK14 1447/4885MAPK10 2415/4885GCGR 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.